Cargando…
Aptamer-based applications for cardiovascular disease
Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in v...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606242/ https://www.ncbi.nlm.nih.gov/pubmed/36312558 http://dx.doi.org/10.3389/fbioe.2022.1002285 |
_version_ | 1784818250208509952 |
---|---|
author | Chen, Xinyuan Ma, Yue Xie, Yuquan Pu, Jun |
author_facet | Chen, Xinyuan Ma, Yue Xie, Yuquan Pu, Jun |
author_sort | Chen, Xinyuan |
collection | PubMed |
description | Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo, enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research. |
format | Online Article Text |
id | pubmed-9606242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96062422022-10-28 Aptamer-based applications for cardiovascular disease Chen, Xinyuan Ma, Yue Xie, Yuquan Pu, Jun Front Bioeng Biotechnol Bioengineering and Biotechnology Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo, enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606242/ /pubmed/36312558 http://dx.doi.org/10.3389/fbioe.2022.1002285 Text en Copyright © 2022 Chen, Ma, Xie and Pu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Chen, Xinyuan Ma, Yue Xie, Yuquan Pu, Jun Aptamer-based applications for cardiovascular disease |
title | Aptamer-based applications for cardiovascular disease |
title_full | Aptamer-based applications for cardiovascular disease |
title_fullStr | Aptamer-based applications for cardiovascular disease |
title_full_unstemmed | Aptamer-based applications for cardiovascular disease |
title_short | Aptamer-based applications for cardiovascular disease |
title_sort | aptamer-based applications for cardiovascular disease |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606242/ https://www.ncbi.nlm.nih.gov/pubmed/36312558 http://dx.doi.org/10.3389/fbioe.2022.1002285 |
work_keys_str_mv | AT chenxinyuan aptamerbasedapplicationsforcardiovasculardisease AT mayue aptamerbasedapplicationsforcardiovasculardisease AT xieyuquan aptamerbasedapplicationsforcardiovasculardisease AT pujun aptamerbasedapplicationsforcardiovasculardisease |